Fresenius focuses on data, computer lapses at Akorn in trial over $4.3B deal
admin 12th July 2018 Uncategorised 0A trial which will determine whether Germany’s Fresenius can cancel its $4.3 billion deal to buy out U.S. generics maker Akorn is focused on lapses in Akorn’s computer and data integrity. Fresenius says it is justified in killing the deal, while Akorn counters that Fresenius has buyer’s remorse.
More: Fresenius focuses on data, computer lapses at Akorn in trial over .3B deal
Source: fierce